Quarterly report pursuant to Section 13 or 15(d)

EMPLOYEE AND DIRECTOR BENEFITS

v2.4.0.6
EMPLOYEE AND DIRECTOR BENEFITS
3 Months Ended
Mar. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]  
EMPLOYEE AND DIRECTOR BENEFITS

NOTE 6 - EMPLOYEE AND DIRECTOR BENEFITS

 

Stock Options

 

At March 31, 2013, the Company had stock-based compensation plans as described below. The compensation cost that has been charged to earnings for the plans was approximately $259,000 for the three months ended March 31, 2013 and 2012.

 

The Company’s 2005 Amended and Restated Stock Option Plan allows for the grant of stock options to purchase up to 1,025,000 shares of the Company’s common stock. The Company’s 2009 Stock Incentive Plan authorizes the grant of up to 425,000 shares and allows for the issuance of Stock Appreciation Rights, Restricted Stock, Stock Options, Non-stock Share Equivalents, Performance Shares or Performance Units. Both plans allow for the grant of incentive stock options and non-qualified stock options, and awards are generally granted with an exercise price equal to the estimated fair market value of the Company’s common stock at the date of grant. The maximum term of the options granted under the plans is ten years.

 

The Company has granted non-plan options to certain persons representing key business relationships to purchase up to an aggregate amount of 55,000 shares of the Company’s common stock at between $15.00 and $20.00 per share for ten years. These options are non-qualified and not part of either plan.

 

The Company estimates the fair value of each stock option award using a Black-Scholes-Merton valuation model that uses the assumptions noted in the following table. Expected volatilities are based on an index of southeastern United States publicly traded banks. The expected term for options granted is based on the short-cut method and represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the U. S. Treasury yield curve in effect at the time of grant.

 

    2013     2012  
Expected volatility     18.50 %     20.00 %
Expected term (in years)     7 years       5 years  
Risk-free rate     1.39 %     0.92 %

 

The weighted average grant-date fair value of options granted during the three months ended March 31, 2013 and March 31, 2012 was $8.03 and $5.89, respectively.

 

The following table summarizes stock option activity during the three months ended March 31, 2013 and March 31, 2012:

 

          Weighted        
      Weighted     Average        
      Average     Remaining        
      Exercise     Contractual     Aggregate  
  Shares     Price     Term (years)     Intrinsic Value  
  (In Thousands)  
Three Months Ended March 31, 2013:                        
Outstanding at January 1, 2013     816,500     $ 20.87       5.8     $ 9,905  
Granted     25,000       33.00       10.0       -  
Exercised     (9,000 )     10.00       2.2       207  
Outstanding at March 31, 2013     832,500       21.35       5.7     $ 9,698  
                               
Exercisable at March 31, 2013     458,995     $ 14.37       3.5     $ 8,550  
                               
Three Months Ended March 31, 2012:                                
Outstanding at January 1, 2012     1,073,800     $ 18.33       6.0     $ 12,508  
Granted     25,000       30.00       9.9       -  
Exercised     (33,000 )     11.03       3.8       626  
Outstanding at March 31, 2012     1,065,800       13.37       5.9     $ 11,892  
                               
Exercisable at March 31, 2012     411,940     $ 13.37       4.2     $ 6,851  

 

As of March 31, 2013, there was $1,467,000 of total unrecognized compensation cost related to non-vested stock options. The cost is expected to be recognized on the straight-line method over the next 1.9 years.

 

Restricted Stock

 

The Company has issued 68,500 shares of restricted stock to certain employees. The value of restricted stock awards is determined to be the current value of the Company’s stock at the time of grant, and this total value will be recognized as compensation expense over the vesting period, which is five years from the date of grant. As of March 31, 2013, there was $1,473,000 of total unrecognized compensation expense. The expense is expected to be recognized evenly over the remaining 3.9 years of the restricted stock’s vesting period.

 

Stock Warrants

 

The Company granted warrants to purchase common stock of the Company in connection with the issuance of debt. There were 79,000 warrants unexercised as of March 31, 2013, each with an exercise price of $25.00. 64,000 of the warrants expire in September 2013, and the remaining 15,000 expire in June 2016. There were 6,500 warrants exercised during the first quarter of 2013.